From Hyoscine

Care should be taken when moving from another type of anticholinergic drug due to the potential for increased risk of anticholinergic adverse effects.1 There is no available data to support transferring patients from a non-glycopyrronium bromide anticholinergic (e.g. hyoscine/scopolamine or atropine) to Sialanar®.1,2

A washout period from the first drug should be considered. Sialanar® should be prescribed following the dose titration table, starting from dose level 1 to balance efficacy and side effects.

The half-life of free scopolamine is approx. 10 hours so the drug should be cleared within about 72 hours. However, the ultimate decision as to when to start the second drug and the appropriate starting dose should lie with the treating clinician.

From 1mg/5ml glycopyrronium bromide oral solutions:

Oral preparations of glycopyrronium bromide are not interchangeable on a microgram-for-microgram basis due to differences in bioavailability. Care should be taken if switching between oral preparations and dosing adjusted accordingly.3

The document linked below provides guidance on the equivalent doses of 1mg/5ml glycopyrronium bromide oral solutions4-6 and Sialanar® (2mg/5ml glycopyrronium bromide) oral solution1, due to differences in concentration and bioavailability.

References

  1. Sialanar® SmPC (January 2023) https://www.medicines.org.uk/emc/product/2301  – accessed August  2023 
  2. Scopoderm (hyoscine) SmPC (March 2022). https://www.medicines.org.uk/emc/product/13379/smpc - accessed August 2023
  3. BNFC Glycopyrronium Bromide https://bnfc.nice.org.uk/drugs/glycopyrronium-bromide/ - accessed August 2023 
  4. Glycopyrronium Bromide 1 mg/5 ml Oral Solution (Colonis Pharma) SmPC (September 2021) https://www.medicines.org.uk/emc/product/7344/smpc#gref   - accessed August 2023 
  5. Glycopyrronium Bromide 1 mg/5 ml Oral Solution (Rosemont Pharmaceuticals Limited) SmPC (December 2021) https://www.medicines.org.uk/emc/product/13136/smpc  – accessed August 2023 
  6. Glycopyrronium Bromide 1 mg/5 ml Oral Solution (Strandhaven Limited t/a Somex Pharma UK Limited) SmPC (July 2022) https://www.medicines.org.uk/emc/product/14104/smpc  – accessed August 2023 
  7. Parr J.R, Todhunter E, Pennington L, et al. Drooling Reduction Intervention randomized trial (DRI): comparing the efficacy and acceptability of hyoscine patches and glycopyrronium liquid on drooling in children with neurodisability. Arch Dis Child 2017; 1-6. Doi:10. 1136/ archdischild-2017-313763.
  8. Reid S.M, et al. Anticholinergic medications for reducing drooling in children with developmental disability. Developmental Medicine & Child Neurology 2019; 63(3): 346-353

UK-SIA-23-0112 | August 2023

Please see below for information on how to report an adverse event in the UK or Republic of Ireland:

UK
Adverse events should be reported. Reporting forms and information can be found at: www.mhra.gov.uk/yellowcard.
Adverse events should also be reported to Proveca Limited. Phone: 0333 200 1866 E-Mail: medinfo@proveca.com

Republic of Ireland
Adverse events should be reported. Reporting forms and information can be found at: www.hpra.ie.
Adverse events should also be reported to Proveca Limited. Phone: +44 333 200 1866 E-Mail: medinfo@proveca.com

You are now leaving a Proveca website.

Proveca are not responsible for the content on this website.